Advertisements



AstraZeneca PLC (ADR) (AZN) In Respiratory Drug Deal With Circassia Pharmaceuticals

In an effort to enhance collaboration with Circassia Pharmaceuticals, AstraZeneca PLC (ADR) (NYSE:AZN) has acquired an equity stake valued.....»»

Category: topSource: insidermonkeyMar 20th, 2017

Concert rebuffed $250M buyout offer from Vertex before CF drug deal

Lexington-based Concert Pharmaceuticals rebuffed a $250 million buyout offer from Vertex Pharmaceuticals in November before ultimately striking a deal earlier this month to sell a cystic fibrosis drug to the Boston company for $160 million, according t.....»»

Category: topSource: bizjournals11 hr. 4 min. ago

AstraZeneca (AZN) Gets Another CRL for ZS-9; Inks COPD Deal

London based AstraZeneca plc (AZN) received a second Complete Response Letter (CRL) from the FDA for its new drug application .....»»

Category: topSource: zacksMar 20th, 2017

Marathon Sells Muscular-Dystrophy Drug to PTC After Pricing Scrutiny

Marathon Pharmaceuticals has struck a deal to sell its muscular dystrophy treatment to PTC Therapeutics, two weeks after a group of U.S. senators began scrutinizing the steroidal drug’s pricing......»»

Category: smallbizSource: wsjMar 16th, 2017

$160M deal with Concert helps Vertex maintain dominance in cystic fibrosis

Vertex Pharmaceuticals' move on Monday to acquire a once-a-day cystic fibrosis drug for $160 million from a 69-employee Lexington-based biotech could help the Boston company maintain its "dominant" position in the CF pharmaceuticals market, accordi.....»»

Category: topSource: bizjournalsMar 6th, 2017

Pieris Pharmaceuticals" stock soars after exclusive license deal with Japan"s ASKA

Shares of Pieris Pharmaceuticals Inc. soared 16% in premarket trade Monday, after the drug maker announced an exclusive license deal with Japan's ASKA Pharmaceutical Co. Ltd. for the development and comm.....»»

Category: topSource: marketwatchFeb 27th, 2017

MedImmune gets OK from China to pursue arthritis drug in joint venture deal

Gaithersburg-based MedImmune is expanding its footprint in China's drug market after receiving a permit to begin clinical trials there on a biologic therapy for rheumatoid arthritis. MedImmune, which is the R&D arm for London-based AstraZeneca (NYSE:.....»»

Category: topSource: bizjournalsJan 19th, 2017

Japan"s Takeda ready for fresh acquisitions after $5.2 billion Ariad deal

Japan's Takeda Pharmaceutical Co said it has the financial capacity for fresh acquisitions to bolster its drug portfolio after agreeing on Monday to acquire cancer drug maker Ariad Pharmaceuticals in a $5.20 billion deal......»»

Category: topSource: foxnewsJan 10th, 2017

Japan"s Takeda ready for fresh acquisitions after $5.2 billion Ariad deal

TOKYO (Reuters) - Japan's Takeda Pharmaceutical Co said it has the financial capacity for fresh acquisitions to bolster its drug portfolio after agreeing on Monday to acquire cancer drug maker Ariad Pharmaceuticals in a $5.20 billion deal......»»

Category: topSource: reutersJan 9th, 2017

Japanese drugmaker to buy US cancer drug developer

Japanese drugmaker Takeda Pharmaceutical will buy U.S. cancer drug developer Ariad Pharmaceuticals in a $5.2 billion deal that the companies expect to close by the end of February......»»

Category: topSource: moneycentralJan 9th, 2017

Merrimack Pharmaceuticals" Stock Soars On Heavy Volume After Drug Sale Deal

Shares of Merrimack Pharmaceuticals Inc. soared 34% in active premarket trade Monday, after the company announced a deal to sell some drug products to France-based Ipsen SA for up to $1.03 billion......»»

Category: topSource: foxnewsJan 9th, 2017

Merrimack Pharmaceuticals" stock soars on heavy volume after drug sale deal

Shares of Merrimack Pharmaceuticals Inc. soa.....»»

Category: topSource: marketwatchJan 9th, 2017

Japan"s Takeda to buy U.S. cancer drug maker Ariad in $5.2 billion deal

(Reuters) - Japan's Takeda Pharmaceutical Co Ltd said on Monday it would buy cancer drug maker Ariad Pharmaceuticals Inc in a deal valued at $5.20 billion, to beef up its oncology pipeline......»»

Category: topSource: reutersJan 9th, 2017

Biogen: Starting the New Year Off With a Bang?

When Ionis Pharmaceuticals (IONS) announced that its spinal muscular atrophy treatment had been approved by the FDA, it was almost as big a deal for Biogen (BIIB), which will get to market the drug, as it was for its smaller b.....»»

Category: blogSource: barronsDec 29th, 2016

Ionis Pharmaceuticals earns $28M from AstraZeneca for new cancer drug

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual investors, professional money managers, active trader.....»»

Category: blogSource: theflyonthewallDec 16th, 2016

Lonza to buy U.S. drug capsules maker Capsugel from KKR for $5.5 billion

(Reuters) - Lonza Group AG announced its biggest ever acquisition on Thursday with a deal to buy Capsugel, a U.S. maker of capsule products and other drug delivery systems, for $5.5 billion in cash to broaden its product range as a pharmaceuticals industr.....»»

Category: topSource: reutersDec 15th, 2016

Sanofi in Deal Talks With Actelion Pharmaceuticals

French drug giant Sanofi is in talks for a deal with Actelion Pharmaceuticals. Meanwhile, Johnson & Johnson abandoned its pursuit of the Swiss drug company......»»

Category: smallbizSource: wsjDec 14th, 2016

Sanofi in Talks for Deal With Actelion Pharmaceuticals

French drug giant Sanofi SA is in talks for a deal with Actelion Pharmaceuticals Ltd., according to people familiar with the matter. Meanwhile, Johnson & Johnson abandoned its pursuit of the Swiss drug company......»»

Category: smallbizSource: wsjDec 14th, 2016

Sanofi Is in Talks for Deal With Actelion Pharmaceuticals - Wall Street Journal

Wall Street JournalSanofi Is in Talks for Deal With Actelion PharmaceuticalsWall Street JournalFrench drug giant Sanofi SA is in talks for a deal with Actelion Pharmaceuticals Ltd., according to people familiar with the matter, as Johnson & Johnson abando.....»»

Category: topSource: googlenewsDec 13th, 2016

Sanofi is in talks for deal with Actelion Pharmaceuticals

French drug giant Sanofi SA is in talks for a deal with Actelion Pharmaceuticals Ltd., according to people familiar with the matter, as Johnson & Johnson abandons its pursuit of the Swiss drug company......»»

Category: smallbizSource: wsjDec 13th, 2016

Johnson & Johnson Pulls Out of Talks to Buy Actelion - Wall Street Journal

Wall Street JournalJohnson & Johnson Pulls Out of Talks to Buy ActelionWall Street JournalJohnson & Johnson pulled out of talks to buy Swiss drug company Actelion Pharmaceuticals Ltd. after the price needed to seal the deal got too high. New Brunswick, N......»»

Category: topSource: googlenewsDec 13th, 2016